Silo Pharma Registers 3.07M Shares for Resale, Eyes $2.38M from Warrants

TL;DR

**Silo Pharma's S-1 filing for warrant-related share resale is a mixed bag, offering potential cash but also dilution risk; watch for warrant exercise above current trading price.**

AI Summary

Silo Pharma, Inc. (SILO) filed an S-1 registration statement on October 28, 2025, for the resale of up to 3,071,428 shares of common stock. These shares are issuable upon the exercise of Investor Warrants to purchase 2,857,143 shares at an exercise price of $0.75 per share, and Placement Agent Warrants to purchase 214,285 shares at an exercise price of $1.0938 per share. The Investor Warrants were issued to accredited investors on October 1, 2025, and the Placement Agent Warrants were issued to H.C. Wainwright & Co., LLC on the same date. While Silo Pharma will not receive proceeds from the resale of these shares by Selling Shareholders, it could receive approximately $2.38 million if all 3,071,428 warrants are exercised for cash. The company is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company, focusing on novel therapeutics for PTSD, stress-induced anxiety, fibromyalgia, and CNS diseases, including psychedelic formulations like SPC-15 and SP-26. The common stock is listed on the Nasdaq Capital Market under the symbol "SILO", with a last reported sale price of $0.5690 on October 27, 2025.

Why It Matters

This S-1 filing signals a potential increase in the float of Silo Pharma's common stock, which could exert downward pressure on the share price, currently at $0.5690. For investors, the exercise of warrants at $0.75 and $1.0938, above the current market price, indicates a potential future cash infusion of $2.38 million for the company, which could fund its developmental-stage biopharmaceutical pipeline. However, the uncertainty of warrant exercise poses a risk. Competitively, this capital could help advance its psychedelic and traditional therapeutic programs, such as SPC-15 for PTSD, in a rapidly evolving biopharma landscape.

Risk Assessment

Risk Level: medium — The risk level is medium due to the potential for significant dilution from the resale of up to 3,071,428 shares, which could depress the stock price from its October 27, 2025, closing price of $0.5690. While the company could receive approximately $2.38 million from warrant exercises, there is no guarantee these warrants will be exercised, especially if the stock price remains below the $0.75 and $1.0938 exercise prices.

Analyst Insight

Investors should monitor the trading volume and price action of SILO closely for signs of increased selling pressure from the Selling Shareholders. Consider the potential for dilution against the speculative upside of its developmental-stage biopharmaceutical pipeline, particularly the $2.38 million potential cash infusion from warrant exercises if the stock price recovers above the exercise prices.

Key Numbers

• 3,071,428 — Shares of Common Stock (Maximum shares registered for resale upon warrant exercise)
• $0.75 — Investor Warrant Exercise Price (Price at which 2,857,143 Investor Warrants can be exercised)
• $1.0938 — Placement Agent Warrant Exercise Price (Price at which 214,285 Placement Agent Warrants can be exercised)
• $2.38M — Potential Gross Proceeds (Aggregate gross proceeds if all 3,071,428 warrants are exercised for cash)
• $0.5690 — Last Reported Sale Price (Silo Pharma Common Stock price on October 27, 2025)
• 2,857,143 — Investor Warrant Shares (Number of shares underlying Investor Warrants)
• 214,285 — Placement Agent Warrant Shares (Number of shares underlying Placement Agent Warrants)
• October 1, 2025 — Warrant Issuance Date (Date Investor and Placement Agent Warrants were issued)
• 5-year anniversary — Investor Warrant Expiration (Expiration period for Investor Warrants from registration statement effective date)
• September 29, 2030 — Placement Agent Warrant Expiration (Expiration date for Placement Agent Warrants)

Key Players & Entities

• Silo Pharma, Inc. (company) — Registrant in S-1 filing
• SILO (company) — Ticker symbol on Nasdaq Capital Market
• U.S. Securities and Exchange Commission (regulator) — Recipient of S-1 filing
• Eric Weisblum (person) — Chief Executive Officer of Silo Pharma, Inc.
• H.C. Wainwright & Co., LLC (company) — Exclusive placement agent for warrants
• Richard Friedman, Esq. (person) — Legal counsel from Sheppard Mullin Richter & Hampton LLP
• University of Maryland, Baltimore (company) — License agreement partner for Ketamine polymer implant
• Columbia University (company) — Sponsored research agreement partner for Alzheimer's and depression disorders
• $0.75 (dollar_amount) — Exercise price for Investor Warrants
• $1.0938 (dollar_amount) — Exercise price for Placement Agent Warrants

FAQ

Risk Factors

• Potential Dilution from Warrant Exercise [medium — financial]: The S-1 filing registers 3,071,428 shares issuable upon exercise of warrants. If all warrants are exercised, this could lead to significant dilution for existing shareholders, especially if exercised at a price below the current market price.
• Developmental Stage and Regulatory Hurdles [high — regulatory]: Silo Pharma is a developmental-stage company focusing on novel therapeutics, including psychedelic formulations. This implies a long and uncertain path through clinical trials and regulatory approval processes (e.g., FDA), with a high risk of failure.
• Market Volatility and Stock Price Performance [medium — market]: The company's common stock is trading below the exercise price of the Placement Agent Warrants ($0.5690 vs $1.0938) and close to the Investor Warrant exercise price ($0.5690 vs $0.75). This suggests market skepticism or volatility, increasing the risk that warrants may not be exercised.
• Dual Business Model Risks [medium — operational]: Silo Pharma operates as both a biopharmaceutical company and a cryptocurrency treasury. This dual focus may present unique operational challenges, resource allocation issues, and regulatory complexities across disparate industries.

Industry Context

Silo Pharma operates in the highly competitive and regulated biopharmaceutical sector, focusing on niche areas like PTSD, anxiety, and CNS diseases, including novel psychedelic formulations. The development of such therapeutics requires substantial R&D investment, lengthy clinical trials, and navigating complex regulatory pathways. The company also diversifies into cryptocurrency treasury management, a volatile and emerging sector.

Regulatory Implications

As a developmental-stage biopharmaceutical company, Silo Pharma faces significant regulatory scrutiny from bodies like the FDA. The development of psychedelic-based therapeutics introduces additional regulatory complexities and potential hurdles. The cryptocurrency aspect of its business may also be subject to evolving financial regulations.

What Investors Should Do

1. Monitor Warrant Exercise and Dilution
2. Evaluate Clinical Trial Progress and Regulatory Milestones
3. Assess Risk of Dual Business Model
4. Compare Current Stock Price to Warrant Exercise Prices

Key Dates

• 2025-10-28: S-1 Registration Statement Filed — Initiates the process for resale of shares underlying warrants, providing transparency on potential future share count.
• 2025-10-01: Investor and Placement Agent Warrants Issued — Establishes the terms and potential future dilution from these warrants.
• 2025-10-27: Last Reported Sale Price — Indicates current market valuation of SILO common stock at $0.5690, below warrant exercise prices.
• 2030-09-29: Placement Agent Warrant Expiration — Defines the deadline for H.C. Wainwright & Co., LLC to exercise their warrants.

Glossary

S-1 Registration Statement

A form filed with the U.S. Securities and Exchange Commission (SEC) by companies planning to offer their securities to the public. It contains detailed information about the company's business, financial condition, and the securities being offered. (This filing outlines the potential resale of shares by warrant holders and provides key details about the company's structure and financial instruments.)

Investor Warrants

Options that give the holder the right, but not the obligation, to purchase a company's stock at a specified price (exercise price) before a certain expiration date. (These represent a significant number of shares (2,857,143) that could be added to the public float if exercised, potentially impacting share price and dilution.)

Placement Agent Warrants

Warrants issued to the underwriter or placement agent for their services in a securities offering. They typically have a higher exercise price than investor warrants. (These warrants (214,285) are held by H.C. Wainwright & Co., LLC and have a higher exercise price ($1.0938), indicating their role in the financing.)

Developmental Stage Company

A company that has not yet generated significant revenue and is primarily focused on research and development, often in industries like biotechnology or technology. (Highlights Silo Pharma's early-stage nature, implying higher risk and a longer path to profitability.)

Cryptocurrency Treasury

A company that holds a significant amount of cryptocurrency assets as part of its balance sheet, often for investment or operational purposes. (Indicates a unique and potentially volatile aspect of Silo Pharma's business model, separate from its biopharmaceutical operations.)

Year-Over-Year Comparison

Information regarding previous filings and year-over-year comparisons for metrics like revenue, margins, and specific risks is not available in this S-1 filing, which focuses on the registration of shares for resale upon warrant exercise.

Key Financial Figures

• $0.0001 — ares”) of common stock, par value $0.0001 per share (“Common Stock”),
• $0.75 — Shares”), at an exercise price of $0.75 per share; issued by us to certain accr
• $1.0938 — Agent”), at an exercise price of $1.0938 per share. The Investor Warrants are ex
• $2.38 million — gregate gross proceeds of approximately $2.38 million. However, we cannot predict when and in
• $0.5690 — rted sale price of our Common Stock was $0.5690. This offering will terminate on the e
• $30.8 billion — rapeutics market is projected to exceed $30.8 billion by 2033, SPC-14 presents a promising op

Filing Documents

• ea0262498-s1_silo.htm (S-1) — 293KB
• ea026249801ex5-1_silo.htm (EX-5.1) — 20KB
• ea026249801ex23-1_silo.htm (EX-23.1) — 2KB
• ea026249801ex-fee_silo.htm (EX-FILING FEES) — 13KB
• image_001.jpg (GRAPHIC) — 4KB
• image_002.jpg (GRAPHIC) — 21KB
• ex5-1_001.jpg (GRAPHIC) — 3KB
• 0001213900-25-103188.txt ( ) — 488KB
• ea026249801ex-fee_silo_htm.xml (XML) — 5KB

RISK FACTORS

RISK FACTORS 7 REGISTERED DIRECT OFFERING AND CONCURRENT PRIVATE PLACEMENT 8 SELLING SHAREHOLDERS 8

USE OF PROCEEDS

USE OF PROCEEDS 11 DIVIDEND POLICY 11

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 12

DESCRIPTION OF SECURITIES THAT THE SELLING SHAREHOLDERS ARE OFFERING

DESCRIPTION OF SECURITIES THAT THE SELLING SHAREHOLDERS ARE OFFERING 14 PLAN OF DISTRIBUTION 14 CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS 15 DISCLOSURE OF COMMISSION POSITION ON INDEMNIFICATION FOR SECURITIES ACT LIABILITY 16 LEGAL MATTERS 16 EXPERTS 16 WHERE YOU CAN FIND MORE INFORMATION 16 INCORPORATION OF DOCUMENTS BY REFERENCE 17 i ABOUT THIS PROSPECTUS This prospectus relates to the offer and resale of up to an aggregate of 3,071,428 shares (the “Shares”) of common stock, par value $0.0001 per share (“Common Stock”), of Silo Pharma, Inc. (the “Company”, “we”, “us” or “our”), consisting of shares of Common Stock issuable upon the exercise of: (i) common stock purchase warrants (the “Investor Warrants”), to purchase up to 2,857,143 shares of Common Stock (the “Investor Warrant Shares”), at an exercise price of $0.75 per share; issued by us to certain accredited investors on October 1, 2025 in a concurrent private placement and registered direct transaction pursuant to a securities purchase agreement, dated as of September 29, 2025 (the “Purchase Agreement”); and (ii) common stock purchase warrants (the “Placement Agent Warrants,” together with the Investor Warrants, the “Warrants”) to purchase 214,285 shares of Common Stock (the “Placement Agent Warrant Shares,” together with the Investor Warrant Shares, the “Warrant Shares”) issued to H.C. Wainwright & Co., LLC, as exclusive placement agent (the “Placement Agent”), at an exercise price of $1.0938 per share. The Investor Warrants are exercisable immediately and expire on the 5-year anniversary of the effective date of this registration statement. The Placement Agent Warrants were exercisable immediately upon issuance on October 1, 2025 and expire on September 29, 2030. The holders of the Warrants and the und

View Full Filing

View this S-1 filing on SEC EDGAR